Dallas Defective Drug Attorneys
Texas Drug Recall Lawyers
Nationally Recognized Attorneys Serving Clients Throughout the U.S.
Modern medicine is a wonder. It helps us recover from serious injury and illness. It gives those suffering from serious disorders a new lease on life. At Miller Weisbrod, we commend the work of researchers who push the boundaries of innovation to bring healing to the suffering.
We also understand that defective drugs and medical devices cause unnecessary suffering, permanent injury and death. As a nationally-recognized leader in plaintiff's personal injury trial law, our firm stands ready to take on the manufacturers of defective pharmaceutical drugs, surgical implants and medical devices. From our offices in Dallas, we serve clients throughout Texas and nationwide.
If you suffered a serious, lasting injury or a loved one died as a result of a dangerous and defective drug or medical device, our team of acclaimed personal injury trial attorneys can help you seek the financial compensation and real recovery you deserve.
Congratulation to attorneys Clay Miller, Les Weisbrod, and Max Freeman for being named 2010 Texas Super Lawyers* as presented in Texas Monthly magazine for Super Lawyers, a Thomson Reuters business.
Please contact our main office in Dallas at 214.987.0005 today to schedule a free consultation with an attorney who has substantial experience making manufacturers of defective drugs and medical devices pay.
If you are calling from Los Angeles, Seattle, Denver, Chicago, New York, Miami or anywhere outside the DFW Metroplex, please call us toll free at 888.987.0005. You may also contact us by e-mail now for prompt attention or to request an appointment.
*Super Lawyers magazine identifies the top 5% of attorneys in each state, as chosen by their peers and through the independent research of Law & Politics. Rising Stars names the state's top up-and-coming attorneys. Super Lawyers magazine is published in all 50 states and reaches more than 13 million readers. Super Lawyers is a Thomson Reuters business.
